NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled
NCT04711135 2026-02-12NETTER-PAdvanced Accelerator ApplicationsPhase 2 Active not recruiting11 enrolled 14 charts 2 FDA